Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance  COVID-19 status Phase of research How it helps Latest publication
ACE2 microbody
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/01/2020
ACE2 receptor trap
Potential treatment - pre-clinical evidence Experimental Antiviral Oct/22/2020
ACE2-GpA-RBC
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/10/2021
ACE2‐EVs
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/28/2020
ACE2‐Fc
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/26/2022
ACE2‐TMPRSS2‐EVs
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/28/2020
Aclarubicin
Potential treatment - theoretical effect Experimental Antiviral Oct/19/2020
Ad26.COV2.S
Emergency use authorization Experimental Vaccine Jun/22/2022
Ad5-nCoV
Potential treatment - clinical evidence Experimental Vaccine Aug/14/2020
Ad5-S-nb2
Potential treatment - pre-clinical evidence Experimental Vaccine Aug/21/2020
Adenylate-3'-phosphate-[[2'-deoxy-uridine-5'-phosphate]-3'-phosphate]
Potential treatment - theoretical effect Experimental Antiviral Aug/03/2020
Adjuvanted SARS-CoV-2 Spike protein
Potential treatment - pre-clinical evidence Experimental Vaccine Apr/01/2021
ADM_13083841
Potential treatment - theoretical effect Experimental Antiviral Aug/28/2020
AG0301-COVID19
Potential treatment - pre-clinical evidence Experimental Vaccine Jul/28/2020
Agaric acid
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Alarelin
Potential treatment - theoretical effect Experimental Antiviral Sep/07/2020
ALD-R491
Potential treatment - pre-clinical evidence Experimental Antiviral Oct/12/2021
Alisporivir
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
ALMPHIR
Potential treatment - theoretical effect Experimental Antiviral Dec/01/2020
Aloxistatin
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/27/2021